Cingulate Announces Publication Of CTx-1301 Comparative Bioavailability Study In CNS Drugs, Says Trimodal ADHD Candidate Showed Higher Late-Day Plasma Levels And Fewer Adverse Events vs. Bimodal Comparator
Share
Why It Matters
Cingulate's ADHD medicine showed it stays active longer in your body and caused fewer side effects than a similar medicine being tested. When a company publishes research like this, it suggests their medicine might work better, which is worth watching as they move toward approval.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.